U.S. market Closed. Opens in 1 day 10 hours 39 minutes

HAE | Haemonetics Corporation Stock Overview

(Stock Exchange: NYSE)
Day's Range 65.90 - 69.26
52 Week Range 58.80 - 97.97
Beta 0.39
Implied Volatility 56.48%
IV Rank 58.72%
Day's Volume 838,011
Average Volume 941,277
Shares Outstanding 50,237,500
Market Cap 3,451,316,250
Sector Healthcare
Industry Medical - Instruments & Supplies
IPO Date 1991-05-10
Valuation
Profitability
Growth
Health
P/E Ratio 27.05
Forward P/E Ratio N/A
EPS 2.54
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 3,657
Country USA
Website HAE
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
*Chart delayed
Analyzing fundamentals for HAE we got that it has average fundamentals where Valuation is considered to be fairly valued, Profitability is very poor, Growth is good and Health is passable. For more detailed analysis please see HAE Fundamentals page.

Watching at HAE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on HAE Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙